drugset
drugset / Trial / NCT04487145

Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

NCT04487145 ↗

Phase 4 Completed 194 enrolled University of California, San Francisco Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collabMakerere University · collabYale University · collab
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Open-label prospective intensive pharmacokinetic study of dihydroartemisinin-piperaquine (DP) in HIV-infected children on efavirenz (EFV)-, lopinavir/ritonavir (LPV/r)-, or dolutegravir (DTG)-based antiretroviral therapy (ART) and HIV-uninfected children not on ART. All children will be malaria-uninfected at the time of enrollment.

Timeline

Start
2020-11-23
Primary completion
2022-04-11
Completion
2022-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dihydroartemisinin-piperaquine Unknown — Oral

Indications

HIV infectious disease